Abstract: Topical ophthalmic Nepafenac-based formulations, which are particularly stable from both chemical and physical points of view, are provided.

Abstract: An ophthalmic composition includes Povidone-iodine (PVP-I) at a concentration of between 0.2%-1.0% (w/w). The ophthalmic composition has an aqueous phase and an oil phase, the oil phase constituting medium-chain triglycerides and the oil phase constituting less than 3% of the total weight of the composition.

Abstract: The invention concerns topical ophthalmic preparations in the form of eye-drops in aqueous solution, containing azithromycin (or a pharmacologically acceptable salt thereof) as active ingredient, wherein the azithromycin is solubilized and stabilized by means of ?-cyclodextrins, and in particular by means of the ?-cyclodextrin called sulfobutyl ether ?-cyclodextrin (SBE-?-CD). The proposed preparations have a remarkably high stability, both physical and chemical, which enables its storage at room temperature for the envisaged period of validity for a commercial pharmaceutical product.

Abstract: The invention concerns topical ophthalmic preparations in the form of eye-drops in aqueous solution, containing azithromycin (or a pharmacologically acceptable salt thereof) as active ingredient, wherein the azithromycin is solubilized and stabilized by means of ?-cyclodextrins, and in particular by means of the ?-cyclodextrin called sulfobutyl ether ?-cyclodextrin (SBE-?-CD). The proposed preparations have a remarkably high stability, both physical and chemical, which enables its storage at room temperature for the envisaged period of validity for a commercial pharmaceutical product.

Abstract: The present invention is directed to a viscoelastic composition comprising an aqueous solution having a minimum of about 0.01% w/v and a maximum of about 20% w/v of a viscoelastic polymer based upon the total volume of the viscoelastic composition. Typically, the viscoelastic composition further contains tris[hydroxymethyl]aminomethane and a polyol (for example sorbitol). The present invention also includes methods of use of the new viscoelastic composition and a packaging device.

Abstract: The present invention is a viscoelastic composition, methods of use and a related device, wherein the viscoelastic composition comprises water, a minimum of about 0.01% w/v and a maximum of about 10% w/v of hyaluronic acid or a salt thereof and a minimum of about 0.01% w/v and a maximum of about 10% w/v of hydroxypropylmethylcellulose, wherein the viscoelastic comprises less than 0.01% w/v chondroitin sulfate.